4.0 Article

Screening for genetic causes of growth hormone hypersecretion

Journal

GROWTH HORMONE & IGF RESEARCH
Volume 30-31, Issue -, Pages 52-57

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.ghir.2016.10.004

Keywords

Acromegaly; Gigantism; Somatotropinoma; Aryl hydrocarbon receptor interacting protein gene; Familial isolated pituitary adenoma (FIPA); X-linked acrogigantism (X-LAG) syndrome; GPR101; Multiple endocrine neoplasia; Carney complex; McCune-Albright syndrome

Ask authors/readers for more resources

Growth hormone (GH) secreting pituitary tumors may be caused by genetic abnormalities in a variety of genes including AIP, MEN1, CDKN1B, and PRKAR1A. These can lead to GH secreting pituitary adenomas as an isolated occurrence (e.g. as aggressive sporadic adenomas or in familial isolated pituitary adenomas (FIPA)) or as part of syndromic conditions such as MEN1 or Carney complex. These tumors have more aggressive features than sporadic acromegaly, including a younger age at disease onset and larger tumor size, and they can be challenging to manage. In addition to mutations or deletions, copy number variation at the GPR101 locus may also lead to mixed GH and prolactin secreting pituitary adenomas in the setting of X-linked acrogigantism (X-LAG syndrome). In X-LAG syndrome and in McCune Albright syndrome, mosaicism for GPR101 duplications and activating GNAS1 mutations, respectively, contribute to the genetic pathogenesis. As only 5% of pituitary adenomas have a known cause, efficient deployment of genetic testing requires detailed knowledge of clinical characteristics and potential associated syndromic features in the patient and their family. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available